ZFPM2 and central nervous system cancer: Based on ANOVA analysis, the expression levels of ZFPM2 were significantly different between the glioma grades (P = 0.012, Fig 4), and the astrocytoma subtype grades (P = 0.006, Table 4), which included the most severe grade IV GBM patients.